Status:
COMPLETED
OmegAD (Omega-3 and Alzheimer's Disease)
Lead Sponsor:
Karolinska University Hospital
Conditions:
Alzheimer's Disease
Eligibility:
All Genders
Phase:
NA
Brief Summary
Memory loss and difficulties with thinking associated with Alzheimer's disease (AD) may be due to a deficiency in the brain of a fatty acid named DHA. The aim of this trial is to see if dietary supple...
Eligibility Criteria
Inclusion
- Alzheimer's disease with MMSE 15-30, living in own homes, treated with stable dose of acetylcholine esterase inhibitor for \>3 months and remaining on that treatment for the study period
Exclusion
- Already treated with omega-3 fatty acids, NSAIDs, warfarin, being an alcohol abuser, suffering from serious concomitant disease or not having a caregiver
Key Trial Info
Start Date :
December 1 2000
Trial Type :
INTERVENTIONAL
End Date :
Estimated Enrollment :
204 Patients enrolled
Trial Details
Trial ID
NCT00211159
Start Date
December 1 2000
Last Update
July 31 2017
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Karolinska University Hospital Huddinge
Stockholm, Sweden, S-141 86